Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026
Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026
Summary
The Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026 gives a COVID-19 disease overview, epidemiology overview, current marketed vaccines, unmet needs, pipeline assessment, and market outlook.
The analyst forecast three different potential scenarios for the future use of COVID-19 vaccines -
- The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.
- The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.
- In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.
Scope
This report includes -
- Executive Summary
- Disease Overview: History of the outbreak, Etiology and Pathophysiology
- Epidemiology
- Current Vaccination Options: Includes detailed product profiles with SWOT analysis
- Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights
- Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis
- R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making
- Market Outlook
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
1 Executive Summary
2 Disease Overview
3 Epidemiology
4 Current Vaccination Options
5 Unmet Needs and Opportunities
6 Pipeline Assessment
7 R&D Strategies
8 Market Outlook
9 Appendix
10 Contact Us
Companies Mentioned
- Pfizer
- BioNTech
- Moderna
- AstraZeneca
- Johnson & Johnson
- Novavax
- CureVac
- Sanofi
- GlaxoSmithKline
- Arcturus
- Medicago
- Valneva
- Inovio
2024 USA Respiratory Disease Testing Market: Shares and Segment Forecasts--Adenovirus, Coronavirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis
About This ReportThis new 283-page report presents detailed analysis of the US Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Coronavirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV
USD 1850 View Report2024 UK Respiratory Disease Testing Market: Shares and Segment Forecasts--Adenovirus, Coronavirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis
About This ReportThis new 281-page report presents detailed analysis of the UK Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Coronavirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV
USD 1850 View ReportCoronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is
USD 1495 View ReportCoronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the
USD 2495 View ReportFill The Form For Sample Request